Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Bladder Urothelial Carcinoma · Bladder Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Contact: Principal Investigator (Tianxin Lin, Professor)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Muscle Invasive Bladder Urothelial Carcinoma · Stage II Bladder Cancer AJCC v8 · Stage IIIA Bladder Cancer AJCC v8

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Gilbert, United States

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Bladder Adenocarcinoma · Bladder Clear Cell Adenocarcinoma · Bladder Mixed Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Anchorage, United States

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Bladder Cancer · Non-Muscle Invasive Bladder Cancer (NMIBC) · Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Iowa City, United States

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer · Non-Muscle Invasive Bladder Urothelial Carcinoma

Abroad (travel likely)RecruitingPHASE2

Tampa, United States · New Brunswick, United States